Ken Griffin Zynerba Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$0.3 - $0.43 $30 - $43
100 New
100 $0
Q4 2022

Feb 14, 2023
SELL
$0.5 - $0.72 $3,150 - $4,536
-6,300 Reduced 43.75%
8,100 $4,000
Q3 2022

Nov 14, 2022
SELL
$0.87 - $1.36 $1,914 - $2,992
-2,200 Reduced 13.25%
14,400 $11,000

Others Institutions Holding ZYNE

# of Institutions
4
Shares Held
774K
Call Options Held
0
Put Options Held
0
View Full List

About Zynerba Pharmaceuticals, Inc.

ZYNE Quotes by TradingView
  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email